Co-transfer of IncFII/IncFIB and IncFII plasmids mediated by IS26 facilitates the transmission of mcr-8.1 and tmexCD1-toprJ1

Table 1 Antibiotic susceptibility testing of TGC-05, TGC-02 and the transconjugants

Strain	AMP	SAM	TZP	CZO	CTT	CRO	CAZ	FEP	ATM	ETP	IPM	AMK	GEN	TOB	CIP	LVX	SXT	TGC	COL
Clinical isolate
TGC-05	≥ 32R	≥ 32R	≤ 4S	≥ 64R	16S	≥ 64R	≥ 64R	2S	≥ 64R	≤ 0.5S	≤ 1S	≥ 64R	≥ 16R	≥ 16R	≥ 4R	≥ 8R	≥ 320R	8	32
TGC-02	≥ 32R	≥ 32R	8S	≥ 64R	≤ 4S	≥ 64R	16R	8SDD	≥ 64R	≤ 0.5S	≤ 1S	≥ 64R	≥ 16R	≥ 16R	≥ 4R	≥ 8R	≥ 320R	8	8
Recipient
EC600	8S	4S	4S	4S	4S	≤ 1S	≤ 1S	≤ 1S	≤ 1S	≤ 0.5S	≤ 1S	≤ 2S	≤ 1S	≤ 1S	< 0.25S	0.5S	≤ 20S	≤ 0.125	≤ 0.5
Transconjugant
JTGC-02-mcr8	8S	4S	≤ 4S	≤ 4S	≤ 4S	≤ 1S	≤ 1S	≤ 1S	≤ 1S	≤ 0.5S	≤ 1S	≤ 2S	≥ 16R	8I	1S	1S	≥ 320R	0.5	4
JTGC-02-Apr	16I	4S	≤ 4S	≤ 4S	≤ 4S	≤ 1S	≤ 1S	≤ 1S	≤ 1S	≤ 0.5S	≤ 1S	≤ 2S	≥ 16R	≥ 16R	0.5S	1S	≤ 20S	0.125	0.5
JTGC-02–1-Tmex	16I	4S	≤ 4S	≤ 4S	≤ 4S	≤ 1S	≤ 1S	≤ 1S	≤ 1S	≤ 0.5S	≤ 1S	≤ 2S	≥ 16R	≥ 16R	≥ 4R	2S	≥ 320R	0.5	2
JTGC-02–2-Tmex	16I	8S	≤ 4S	≤ 4S	≤ 4S	≤ 1S	≤ 1S	≤ 1S	≤ 1S	≤ 0.5S	≤ 1S	≤ 2S	≥ 16R	≥ 16R	≥ 4R	2S	≥ 320R	0.25	2

MIC Minimal inhibitory concentrations, AMP ampicillin, SAM ampicillin/sulbactam, TZP piperacillin/tazobactam, CZO cefazolin, CTT cefotetan, CRO cefatriaxone, CAZ ceftazidime, FEP cefepime, ATM aztreonam, ETP ertapenem, IMP imipenem, AMK amikacin, CEN gentamicin, TOB tobramycin, CIP ciprfloxacin, LVX levofloxacin, SXT trimethoprim/sulfamethoxazole, TGC tigecycline, COL colistin

ISSN: 1476-0711